Regeneron says Phase 3 OPTIMA extension shows zero new HO lesions with Pasatru in adult FOP patients through week 84

• Regeneron reported 84-week Phase 3 OPTIMA extension results for Pasatru in adults with fibrodysplasia ossificans progressiva, presented at ASBMR.
• Extension data showed sustained suppression of new abnormal bone growth, supporting longer-term disease control beyond the initial placebo-controlled period.
• Clinician-assessed flare-ups stayed lower on treatment versus placebo, reinforcing the drug’s disease-modifying profile in the trial population.
• Safety remained broadly consistent with earlier findings, with infections rising at higher dosing; no deaths were reported.
• Regeneron plans to start a Phase 3 OPTIMA 2 study in adolescents and children later this year, expanding the commercial opportunity.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regeneron Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610121206PRIMZONEFULLFEED9843550) on October 12, 2026, and is solely responsible for the information contained therein.